In this webinar, Mikalai Malinouski Ph.D.demonstrated how BioSymetrics uses AI in the prediction of mechanism of action (MOA), and provided a an example of how machine learning workflows can benefit both novel drug discovery and drug repositioning.
BioSymetrics Mechanism of Action Prediction Platform framework will be put to work both in prioritizing chemical libraries and in predicting mechanism for identified compounds. Per the three COVID-19 research initiatives announced by the SCN in the post below, we will be working with William Stanford, Amy Wong, Molly Shoichet, Stephen Juvet, Samira Mubareka, Scott Gray-Own, and Mitchel Sabloff as a component of their research. We will also have the opportunity to screen one of our
The MaRS community has been very welcoming to us. We are honored to have been listed among these prestigious start-up companies working around the clock to address the COVID-19 crisis. https://marsdd.com/magazine/how-canadian-startups-are-tackling-the-covid-19-crisis/
Artificial Intelligence and Machine Learning (Episode 214) Dr. Kevin Folta discusses how the genomics era has generated tremendous data sets, yet the information they reveal is limited by the human biases that search them. Are there ways to examine complex data sets for hidden patterns that can unearth new perspectives in biology? This is the role of machine learning, and the patterns form the basis of artificial intelligence that then executes new tasks. While these
The Business of Healthcare Podcast, Episode 48: Artificial Intelligence and Machine Learning for Healthcare Anthony Iacovone, Chairman of BioSymetrics, joins host Dr. Bob Kaiser for a discussion about what biomedical artificial intelligence and machine learning are and how they can be used to improve outcomes in the areas of drug discovery, clinical diagnostics and value-based care as well as reduce healthcare costs. The Business of Healthcare is a twice-monthly podcast from the Center for Healthcare
The latest episode of Talking Precision Medicine podcast, our own Gabe Muso, speaks with Rafael Rosengarten CEO of Genialis on the practice of improving data preprocessing for the advancement of machine learning in medicine.